Novel therapeutic for multiple sclerosis protects white matter function in EAE mouse model

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Multiple sclerosis (MS) is a chronic demyelinating disease characterized by significant axon dysfunction.
• Previous research showed major histocompatibility complex Class II constructs could reverse experimental autoimmune encephalomyelitis (EAE) symptoms by inhibiting macrophage migration inhibitory factors (MIF) and extracellular signal-regulated kinase (ERK) activation.
• These constructs also promoted remyelination and reduced inflammation.

Purpose of the Study:

• To evaluate the effects of a novel third-generation construct, DRhQ, on axon integrity in the EAE mouse model.
• To assess DRhQ's impact on both myelinated and unmyelinated axons in distinct white matter tracts.
• To determine DRhQ's therapeutic potential for progressive MS, including its effect on ischemic vulnerability.

Main Methods:

• Electrophysiology was used to compare axon conduction properties in corpus callosum slices and optic nerves of EAE mice.
• The study examined the effects of EAE and DRhQ treatment on axon excitability, conduction velocity, and spatiotemporal summation.
• Investigated the increased vulnerability of white matter to ischemia in the EAE model and the protective effects of DRhQ.

Main Results:

• EAE induced alterations in axon excitability, delayed conduction, and slowed summation, correlating with astrocyte and microglia activation.
• DRhQ treatment post-EAE onset significantly inhibited microglial and astrocyte activation.
• DRhQ administration improved the functional integrity of myelinated axons and enhanced recovery from white matter ischemia.

Conclusions:

• DRhQ treatment administered after EAE onset promotes white matter integrity and function.
• DRhQ reduces the increased vulnerability to ischemic injury observed in the EAE MS model.
• These findings suggest DRhQ has significant therapeutic potential for progressive multiple sclerosis.